Bone and renal safety profile at 72 weeks after switching to tenofovir alafenamide in chronic hepatitis B patients.
Brian T LeeMimi ChangCarolina LimHo S BaeTse-Ling FongPublished in: JGH open : an open access journal of gastroenterology and hepatology (2020)
CHB patients who switch from long-term TDF to TAF therapy show sustained improvement in proximal tubular function and hip BMD. Weight gain was noted, and long-term studies are needed to evaluate its effect on patient outcomes.
Keyphrases
- weight gain
- end stage renal disease
- body mass index
- ejection fraction
- birth weight
- newly diagnosed
- chronic kidney disease
- hepatitis b virus
- prognostic factors
- peritoneal dialysis
- weight loss
- gestational age
- patient reported outcomes
- total hip arthroplasty
- soft tissue
- patient reported
- postmenopausal women
- liver fibrosis